The biological activity sensors in development consist of nanoparticles conjugated with a peptide substrate produce fluorescence in urine associated with immunotherapy response.
Elypta anticipates launching a test to conduct surveillance for recurrence of renal cell carcinoma in patients that have undergone surgery.
The researchers said that their deep-learning interpreter of outcomes for patients with gliomas could be more accurate and objective than pathologists.
Winship's director of the cancer tissue and pathology shared resource said that some labs aren't leveraging molecular technologies due to reimbursement issues.
The British molecular diagnostics company plans to make its array-based test for early-stage Alzheimer's disease available in the US by year end.